2018 AANS Annual Scientific Meeting-History and Potential Future Applications of Oncolytic Virus Therapy

History and Potential Future Applications of Oncolytic Virus Therapy

Video Transcription

Video Summary

In this video, Dr. Robert Martuza from Massachusetts General Hospital presents on the history and potential future applications of oncolytic virus therapy. He discusses the promise of oncolytic viruses in cancer therapy, including selective tumor replication, anti-tumor immunity, and reducing the need for personalized cell therapies. Dr. Martuza describes the development of various oncolytic viruses, such as G207 and G47 Delta, which have shown success in preclinical and clinical trials for glioblastoma. He highlights the concept of in-situ vaccination, where a virus injected into one tumor can induce an immune response that helps reject tumors elsewhere. This approach has been further enhanced by the addition of immune checkpoint inhibitors and cytokines, which improve the overall outcome and create an immunologically hot tumor. Dr. Martuza concludes by discussing the ongoing clinical trials and potential future applications of oncolytic virus therapy, emphasizing the need for collaboration and exploring synergies with other therapies. The video was presented at the 11th International Oncolytic Virus Conference.

Asset Caption

Introduction - Rohan Ramakrishna, MD, FAANS, Robert L. Martuza, MD, FAANS(L)

Keywords

oncolytic virus therapy

selective tumor replication

anti-tumor immunity

in-situ vaccination

immune checkpoint inhibitors

clinical trials